Who is sponsoring NCT03565289?

NCT03565289 is sponsored by ProteoMediX AG.

What drugs are being tested in NCT03565289?

Interventions in NCT03565289: Blood sample collection.

What condition does NCT03565289 study?

NCT03565289 studies Indication for Prostate Biopsy Due to Suspected Prostate Cancer.

Is NCT03565289 still recruiting?

NCT03565289 is currently completed. Last updated 16 December 2020.

Last reviewed 2020-12-16 · How we verify

NCT03565289: PROPOSe

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PRospective Prostate biOmarker Study

Completed Last updated 16 December 2020

What this trial tests

trial testing Blood sample collection in Indication for Prostate Biopsy Due to Suspected Prostate Cancer in 455 participants. Completed in 31 January 2020.

Timeline

14 August 2018

Primary endpoint
31 December 2019

31 January 2020

Quick facts

Lead sponsor	ProteoMediX AG
Status	Completed
Study type	OBSERVATIONAL
Enrollment	455
Start date	14 August 2018
Primary completion	31 December 2019
Estimated completion	31 January 2020
Sites	11 locations across Austria, Germany, Denmark

Drugs / interventions tested

Blood sample collection — full drug profile →

Conditions studied

Indication for Prostate Biopsy Due to Suspected Prostate Cancer — all drugs for Indication for Prostate Biopsy Due to Suspected Prostate Cancer →

Sponsor

ProteoMediX AG

Who can join

Adults 45 to 80, male only, with Indication for Prostate Biopsy Due to Suspected Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

• Correlation of a glycoprotein panel with prostate biopsy outcome and PCa aggressiveness

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer.
Klocker H, Golding B, Weber S, Steiner E, et al · · 2020 · cited 26× · PMID 35474911 · DOI 10.1002/bco2.8

Verify or expand the search:

Other trials of Blood sample collection

Trials testing the same drug.

NCT07243067 — Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer · not yet recruiting
NCT07499921 — Clinical and BIOgical Analyses of RECtal Tumors · NA · not yet recruiting
NCT07516392 — Study of a Polygenic Risk Score to Predict the Risk of Pancreatic Ductal Adenocarcinoma · NA · not yet recruiting
NCT07455136 — A Study to Develop a Blood-based Test for Aiding the Diagnosis/Prognosis of Traumatic Brain Injury in Adults and for Mon · recruiting
NCT07063719 — Identification of Cellular Biomarkers of Rare Eye Diseases in Adults · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03565289 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ProteoMediX AG
Last refreshed: 16 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03565289.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing